Trial Profile
A Single-arm Open-label Phase II Study: Treatment Beyond Progression by Adding Bevacizumab to XELOX or FOLFOX Chemotherapy in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI + Bevacizumab Combination
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AVASTAY
- Sponsors Roche
- 10 Feb 2014 New treatment group added (bevacizumab+FOLFOX) as reported by ClinicalTrials.gov record.
- 10 Feb 2014 New treatment group added (bevacizumab+FOLFOX) as reported by ClinicalTrials.gov record.
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.